Alembic Pharmaceuticals’ joint venture, Aleor Dermaceuticals, has received approval from the Food and Drug Administration for its generic Metrogel Gel (metronidazole gel, 1%).
The topical gel is indicated for the topical treatment of inflammatory rosacea lesions. The full approval follows the company having received a tentative approval from the agency previously.
[Read more: Alembic launches generic Sinequan]
The product had an estimated $29 million U.S. market size for the year ended June 2021, ac-cording to data from IQVIA.
Alembic said that it has received a total of 149 approved generics, including 132 final approvals and 17 tentative approvals from the FDA.